SMA is genetic disease which results in a decrease in the production of SMN, which in turn leads to the death of motor neurons. SMA 0 - II are very severe pediatric conditions with high mortality rates, where as SMA III patients can live into adulthood and will be able to walk unaided for longer than other SMA types, but will need a wheelchair later in life.
SMA III will effect all of the musculature in the body, one of the most devastating for independence and quality of life being the upper body and hands. Loss of the use of ones hands severely hinders their agency.
Due to the physical implications of SMA3, workers afflicted by the disease are drastically hindered in their ability to do work. The average salary of a worker in the United States is $56,516. A patient afflicted with SMA3 estimated that he loses 20% productivity per day due to SMA3. This equates to an overall economic impact of roughly $44,082,480. SMA3 has an average annual incidence rate of 1.5 cases per 100,000 population in the United States [1]. Therefore, the prevalence of persons with SMA3 in the United States ranges from 3,500 to 4,300 people. The female to male ratio is roughly 1:2 and primarily affects children under 1 year of age [1]. Patients with two parents who are carriers of the abnormal SMN gene are at an increased risk of developing SMA3 [2]. Other risk factors include neonatal environmental factors such as exposure to radiation, tobacco and alcohol [3].
Based on the prevalence study discussed in the epidemiology section, the frequency of SMA in the US is 8.5 to10.3 per 100,000 births. Since SMA 0-II patients are typically in a state that is too critical for physical therapy to be a viable solution and SMA IV patients tend to have comparatively mild symptoms, we will instead focus on SMA III patients. There are between 3592 and 4352 SMA III patients in the USA, with 41 to 50 more being born per year. The market of focus for us is the therapy that is used in tandem with the pharmaceuticals rather than direct competition with the drugs themselves. Most treatment regiments suggest a combination approach, so while the pharmaceutical market is very large it is not currently in competition with our market. The typical cost of a physical therapy session is $125.[4] Patients who are seeing a physical therapist for a prolonged period would typically have three appointments every week.[5] This results in an annual cost of $19,500 per patient or an annual market size between $70,044,000 and $84,864,000.
“For years people assumed that if you gave patients simple building-block exercises, that the ability to do complex tasks would improve as general proficiency in Range of Motion, Strength, and Endurance improved. However, what we have discovered in more recent years is that the best way to train patients to do these complex tasks is to have them do them or mimic them as best they can and use these as exercises.” - Dr. Teresa Bisson
Based on the philosophy of mimicking real to life motion and exercises, the idea of using Virtual Reality to guide, engage, and assess hand physical therapy patients became a effective and novel solutions. Our task was to create a prototype of hardware that could aid in this goal.
[1] C. Lally, C. Jones, W. Farwell, S. P. Reyna, S. F. Cook, and W. D. Flanders, “Indirect estimation of the prevalence of spinal muscular atrophy Type I, II, and III in the United States,” Orphanet journal of rare diseases, 28-Nov-2017. [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5704427/. [Accessed: 13-Oct-2020].
[2] Puskas, M., 2020. Spinal Muscular Atrophy | Cedars-Sinai. [online] Cedars-sinai.org. Available at: <https://www.cedars-sinai.org/health-library/diseases-and-conditions/s/spinal-muscular-atrophy.html> [Accessed 13 October 2020].
[3] M. S. M. Abdou, A. A. R. Sherif, I. M. H. Wahdan, and K. S. E. D. Ashour, “Pattern and risk factors of congenital anomalies in a pediatric university hospital, Alexandria, Egypt,” The Journal of the Egyptian Public Health Association, 2019. [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6326997/. [Accessed: 13-Oct-2020].
[4] “2020 Physical Therapy Costs: Sessions With & Without Insurance,” Thervo. [Online]. Available: https://thervo.com/costs/physical-therapycost. [Accessed: 12-Oct-2020].
[5] “How Often Do I Need to See a Physical Therapist?,” Spine and Sports Medicine, 12-Dec-2015. [Online]. Available:
https://www.spineandsports.com/often-see-physical-therapist/. [Accessed: 12-Oct-2020].
[6] “WO2012165882A2 - Apparatus for rehabilitation exercise, wearable communication apparatus, and application system and method for
applying same,” Google Patents. [Online]. Available: https://patents.google.com/patent/WO2012165882A2/en?q=%28smart+glove%29.
[Accessed: 12-Oct-2020].
[7] J. Dascal, M. Reid, W. W. IsHak, B. Spiegel, J. Recacho, B. Rosen, and I. Danovitch, “Virtual Reality and Medical Inpatients: A Systematic
Review of Randomized, Controlled Trials,” Innovations in clinical neuroscience, 01-Feb-2017. [Online].
Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5373791/. [Accessed: 12-Oct-2020].
[8] "WHY SPINRAZA/LATER-ONSET STUDIES", Spinraza. [Online]. Available:
https://www.spinraza.com/en_us/home/why-spinraza/how-spinraza-works.html. [Accessed :10/20/2020].